- Home
- SENEB vs OCEAW Comparison
SENEB vs OCEAW Comparison
Compare SENEB & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- OCEAW
- Stock Information
- Founded
- SENEB 1949
- OCEAW N/A
- Country
- SENEB United States
- OCEAW United States
- Employees
- SENEB N/A
- OCEAW 7
- Industry
- SENEB Packaged Foods
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- OCEAW Health Care
- Exchange
- SENEB Nasdaq
- OCEAW Nasdaq
- Market Cap
- SENEB 554.6M
- OCEAW N/A
- IPO Year
- SENEB N/A
- OCEAW 2021
- Fundamental
- Price
- SENEB $88.07
- OCEAW $0.02
- Analyst Decision
- SENEB
- OCEAW
- Analyst Count
- SENEB 0
- OCEAW 0
- Target Price
- SENEB N/A
- OCEAW N/A
- AVG Volume (30 Days)
- SENEB 340.0
- OCEAW N/A
- Earning Date
- SENEB 02-06-2025
- OCEAW N/A
- Dividend Yield
- SENEB N/A
- OCEAW N/A
- EPS Growth
- SENEB 25.61
- OCEAW N/A
- EPS
- SENEB 5.45
- OCEAW N/A
- Revenue
- SENEB $1,541,031,000.00
- OCEAW N/A
- Revenue This Year
- SENEB N/A
- OCEAW N/A
- Revenue Next Year
- SENEB N/A
- OCEAW N/A
- P/E Ratio
- SENEB $15.56
- OCEAW N/A
- Revenue Growth
- SENEB 4.01
- OCEAW N/A
- 52 Week Low
- SENEB $50.11
- OCEAW N/A
- 52 Week High
- SENEB $90.00
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- SENEB 74.42
- OCEAW N/A
- Support Level
- SENEB $77.01
- OCEAW N/A
- Resistance Level
- SENEB $81.00
- OCEAW N/A
- Average True Range (ATR)
- SENEB 0.33
- OCEAW 0.00
- MACD
- SENEB 0.51
- OCEAW 0.00
- Stochastic Oscillator
- SENEB 79.52
- OCEAW 0.00
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.